

PATENT  
09/162,648  
Docket: SEQ-2

CLAIM AMENDMENTS

1. ~~(Cancelled)~~ A method for treating cancer in a human patient, comprising:
- ~~a) implanting at or around the site of a resectable tumor in the patient a first cell population containing alloactivated lymphocytes that are allogeneic to leukocytes in the patient, such that tumor is left at the site; and~~
  - ~~b) implanting at or around the site of a tumor in the patient a second cell population containing alloactivated lymphocytes that are allogeneic to leukocytes in the patient;~~
- ~~wherein step a) and step b) are separated by an interval of at least three days, whereby the treatment stimulates a response by the patient against the tumor.~~
- 2 to 9. ~~(Cancelled)~~
10. (Currently amended) The method of claim 4 claim 23, further comprising removing any residual tumor at or around the site of the second cell population at a time subsequent to when the second cell population was implanted.
11. (Currently amended) The method of claim 4 claim 23, wherein both the first and second cell populations have one or more of the following features:
- i) contain between about  $2 \times 10^9$  and  $2 \times 10^{10}$  cultured peripheral blood mononuclear cells originating from the donor and between about  $1 \times 10^8$  and  $2 \times 10^9$  cultured peripheral blood mononuclear cells originating from the patient or from a second donor;
  - ii) are obtained by a process in which donor lymphocytes are alloactivated by coculturing ex vivo with stimulator leukocytes for a period of about 48 to 72 hours; or
  - iii) are obtained by a process in which donor lymphocytes are alloactivated by coculturing ex vivo with stimulator leukocytes and harvested at about the time of initial alloactivation, measurable by acridine orange or CD69 assay.
- 12 to 19. ~~(Cancelled)~~

PATENT  
09/162,648  
Docket: SEQ-2

20. *(Previously presented)* A pharmaceutical composition comprising alloactivated lymphocytes allogeneic to leukocytes in a cancer patient packaged with information for the treatment of the patient according to the method of claim 23.
- 21 to 22. *(Cancelled)*
23. *(Previously presented)* An improvement in the method of treating a human patient having a tumor by implanting at or around the site of a solid tumor in the patient a cell population comprising alloactivated lymphocytes that are allogeneic to the patient;  
wherein the implanting of the alloactivated lymphocytes results in the patient generating a therapeutic response against tumor growth;  
the improvement comprising implanting at or around the site of a solid tumor in the patient a second cell population containing alloactivated lymphocytes that are allogeneic to the patient between 1 and 8 weeks after the implanting of the first cell population.
24. *(Previously presented)* The improved method of claim 23, which elicits an inflammatory response against the tumor.
25. *(Previously presented)* The improved method of claim 23, which elicits an immune response against the tumor.
26. *(Previously presented)* The improved method of claim 23, wherein the alloactivated lymphocytes in at least one of the cell populations are alloactivated against leukocytes of the human patient.
27. *(Previously presented)* The improved method of claim 23, wherein the alloactivated lymphocytes in at least one of the cell populations are alloactivated against leukocytes of a third-party donor different from the patient or the donor of the lymphocytes.
28. *(Previously presented)* The improved method of claim 23, wherein treatment according to the method has at least one of the following effects in at least 30% of treated subjects:  
a) substantial regression of the tumor in size;  
b) lack of recurrence of a tumor after removal; or  
c) decrease in rate of formation of metastasis.
29. *(Previously presented)* The improved method of claim 23, wherein the tumor is a cancer is selected from melanoma, pancreatic cancer, liver cancer, colon cancer, prostate cancer, and breast cancer.

PATENT  
09/162,648  
Docket: SEQ-2

30. *(Previously presented)* The improved method of claim 23, wherein the first cell population stimulates a response in the patient against the tumor before the implanting of the second cell population.
31. *(Currently amended)* The improved method of claim 23, wherein treatment according to the method has ~~at least one of the following effects:~~ causes
- a) ~~substantial regression of the tumor in size;~~
  - b) ~~lack of recurrence of a tumor after removal -or~~
  - c) ~~decrease in rate of formation of metastasis.~~
32. *(Currently amended)* The method of ~~claim 4~~ claim 23, wherein the first and second cell populations are implanted at or around the site of the same tumor in the patient.